“Fortunately or unfortunately, we are pretty profitable. So actually, we don’t need the money,” says Sajwan of a potential listing of his company.
Ravi Sajwan, founder and CEO of UltraGreen.ai, is not hard-pressed to bring his medtech firm to the public markets, even after announcing a US$188 million ($240.98 million) funding round co-led by Temasek’s 65 Equity Partners that values the company at some US$1.3 billion.
Launched in 2021, 65 Equity Partners has a mandate to support high-growth companies towards a public listing in Singapore. For now, however, an initial public offering (IPO) is not a priority for UltraGreen.ai, which claims to be a global leader in fluorescence-guided surgical technologies and precision healthcare solutions.
